Gurgaon, India

Ranbaxy Laboratories

www.ranbaxy.com
Gurgaon, India

Ranbaxy Laboratories Limited is an Indian multinational pharmaceutical company that was incorporated in India in 1961. The company went public in 1973 and Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in 2008. In 2014, Sun Pharma acquired the entire 63.4% share of Ranbaxy making the conglomerate world’s fifth largest specialty generic pharma company. Ranbaxy exports its products to 125 countries with ground operations in 43 and manufacturing facilities in eight countries. In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. In the Brand Trust Report 2012,Ranbaxy was ranked 161st among India's most trusted brands and subsequently, according to the Brand Trust Report 2013, Ranbaxy was ranked 225th among India's most trusted brands. In 2014 however, Ranbaxy was ranked 184th among India's most trusted brands according to the Brand Trust Report 2014, a study conducted by Trust Research Advisory, a brand analytics company. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

The present invention relates to pure crystalline Form II of an L-malic acid salt of sunitinib and a process for its preparation. The invention further provides crystalline Form II of an L-malic acid salt of sunitinib having a purity of at least 97.0%. The invention also provides crystalline Form II of an L-malic acid salt of sunitinib substantially free of an anti-oxidant. The invention also provides crystalline Form II of L-malic acid salt of sunitinib which remains chemically pure on storage at 25 C.2 C. and 40 C.2 C. at a relative humidity of 60%5% and 75%5%, respectively, for at least 1 month.


Patent
Ranbaxy Laboratories | Date: 2014-01-06

The present invention relates to an ascorbic acid salt of sunitinib and a process for its preparation. The present invention further provides a crystalline Form I of an L-ascorbic acid salt of sunitinib.


Patent
Ranbaxy Laboratories | Date: 2015-06-24

The present invention provides a process for the preparation of crystalline sitagliptin fumarate.


Patent
Ranbaxy Laboratories | Date: 2015-06-24

The present invention relates to pharmaceutical compositions comprising multilayered multiple units and processes for the preparation thereof.


Patent
Ranbaxy Laboratories | Date: 2014-01-08

The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.


Patent
Ranbaxy Laboratories | Date: 2016-04-13

An ethanol-free topical composition for applying to the skin of a subject having a skin disorder such as acne comprises a therapeutically effective amount of isotretinoin, a pharmaceutically acceptable vehicle and one or more pharmaceutically acceptable excipients.


Patent
Ranbaxy Laboratories | Date: 2014-11-13

The present invention relates to oral dispersible compositions comprising a DPP-IV inhibitor and processes for their preparation. It further relates to a method of treating diabetes by administering said oral dispersible compositions.


Patent
Ranbaxy Laboratories | Date: 2014-12-01

The present invention relates to stable oral pharmaceutical compositions comprising solifenacin or a salt thereof prepared by a double compaction process, wherein the amorphous content of solifenacin or a salt thereof in the composition is not less than 80% by weight. It further relates to a method of treating or preventing overactive bladder syndrome by administering said pharmaceutical compositions.


Patent
Ranbaxy Laboratories | Date: 2015-06-10

The present invention relates to an oral pharmaceutical composition of febuxostat which comprises an intragranular component and an extragranular component. Further, it relates to processes for the preparation of said composition and a method of using said composition.


Patent
Ranbaxy Laboratories | Date: 2014-11-20

The present invention relates to a low dose pharmaceutical composition comprising 32 mg or 34 mg doxycycline and one or more pharmaceutically acceptable excipients for the treatment of acne, and processes for its preparation.

Loading Ranbaxy Laboratories collaborators
Loading Ranbaxy Laboratories collaborators